Praziquantel is the only available drug to treat Schistosomiasis. However, its utilization is limited by many drawbacks, including the high therapeutic dose needed, resulting in large tablets and capsules difficult to be swallowed, especially from pediatric patients. In this study, an alternative option to overcome these disadvantages is proposed: to switch to a novel crystalline polymorph of racemic compound praziquantel. The preparation of the crystalline polymorph was realized via a neat grinding process in a vibrational mill. The new phase (Form B) was chemically identical to the starting material (as proved by HPLC, 1H NMR, and polarimetry), but showed different physical properties (as evaluated by SEM, differential scanning calorimetry, thermogravimetry, ATR-FTIR spectroscopy, X-ray powder diffraction, and solid-state NMR). Furthermore, the crystal structure of the new phase was solved from the powder synchrotron X-ray diffraction pattern, resulting in a monoclinic C2/c cell and validated by DFT-D calculation. Moreover the simulated solid-state NMR 13C chemical shifts were in excellent agreement with the experimental data. The conversion of original praziquantel into Form B showed to affect positively the water solubility and the intrinsic dissolution rate of praziquantel. Both the in vitro and in vivo activity against Schistosoma mansoni were maintained. Our findings suggest that the new phase, that proved to be physically stable for at least one year, is a promising product for designing a new praziquantel formulation.

A new soluble and bioactive polymorph of praziquantel

Chierotti, Michele R.;Cerreia Vioglio, Paolo;
2018-01-01

Abstract

Praziquantel is the only available drug to treat Schistosomiasis. However, its utilization is limited by many drawbacks, including the high therapeutic dose needed, resulting in large tablets and capsules difficult to be swallowed, especially from pediatric patients. In this study, an alternative option to overcome these disadvantages is proposed: to switch to a novel crystalline polymorph of racemic compound praziquantel. The preparation of the crystalline polymorph was realized via a neat grinding process in a vibrational mill. The new phase (Form B) was chemically identical to the starting material (as proved by HPLC, 1H NMR, and polarimetry), but showed different physical properties (as evaluated by SEM, differential scanning calorimetry, thermogravimetry, ATR-FTIR spectroscopy, X-ray powder diffraction, and solid-state NMR). Furthermore, the crystal structure of the new phase was solved from the powder synchrotron X-ray diffraction pattern, resulting in a monoclinic C2/c cell and validated by DFT-D calculation. Moreover the simulated solid-state NMR 13C chemical shifts were in excellent agreement with the experimental data. The conversion of original praziquantel into Form B showed to affect positively the water solubility and the intrinsic dissolution rate of praziquantel. Both the in vitro and in vivo activity against Schistosoma mansoni were maintained. Our findings suggest that the new phase, that proved to be physically stable for at least one year, is a promising product for designing a new praziquantel formulation.
127
19
28
www.elsevier.com/locate/ejphabio
https://www.sciencedirect.com/science/article/pii/S0939641117309323?via%3Dihub#s0125
Bioactivity; Crystal structure solution; DFT-D calculations; Mechanochemistry; Neglected tropical diseases; Polymorphism; Praziquantel; Solid-state reactions; Solubility; Animals; Calorimetry, Differential Scanning; Capsules; Crystallization; Powders; Praziquantel; Schistosoma mansoni; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction; Biotechnology; 3003
Zanolla, Debora; Perissutti, Beatrice*; Passerini, Nadia; Chierotti, Michele R.; Hasa, Dritan; Voinovich, Dario; Gigli, Lara; Demitri, Nicola; Geremia, Silvano; Keiser, Jennifer; Cerreia Vioglio, Paolo; Albertini, Beatrice
File in questo prodotto:
File Dimensione Formato  
eur j pharm biopharm2018,127,19_completo.pdf

Accesso riservato

Descrizione: articolo completo
Tipo di file: PDF EDITORIALE
Dimensione 1.96 MB
Formato Adobe PDF
1.96 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
revised Perissutti-et-al -manuscript-complete-EJPB.pdf

Accesso aperto

Descrizione: articolo open access
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.22 MB
Formato Adobe PDF
1.22 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1687641
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 33
social impact